Company intelligence / Profile preview

PharmaEssentia

Taichung, Taichung, Taiwanus.pharmaessentia.com ↗
Ownership
Public · 6446
Development stage
Commercial
01

Overview

PharmaEssentia has successfully developed Ropeginterferon alfa‐2b, marketed as BESREMI®, which has received approval for the treatment of polycythemia vera in both Europe and the United States. The company continues to expand its pipeline targeting hematologic diseases such as MPNs, with ongoing R&D into additional biologics and small molecule therapies. It operates a cGMP biologics facility certified by TFDA and compliant with FDA/EMA standards.

Therapeutic areas
OtherOncologyInfectious Diseases
Modalities
Biologics (notably pegylated interferons)Small molecules and antibodies (in pipeline development)
Industry
Biotech
02

Drug pipeline

4 assets

ropeginterferon alfa-2b

Approved

3 more assets in the full pipeline.

Request access →
03

Partnerships

AOP Orphan Pharmaceuticals AG—co-development of BESREMI® for European market.

Beyond the preview

Go deeper on PharmaEssentia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PharmaEssentia.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call